Skip to main content

Results from a recently published research trial indicate that the new chemotherapy drug CT-2103 (Xyotax™) is effective in some patients with recurrent non-small cell lung cancer.

Lung cancer is the most common cause of cancer-related deaths in the United States and Europe. Non-small cell lung cancer (NSCLC) is a type of cancer that arises from tissue within the lungs. NSCLC may be further defined by the cell type from which it arises, such as adenocarcinoma, squamous carcinoma, large cell carcinoma or undifferentiated carcinoma. Recurrent NSCLC refers to cancer that has recurred following prior therapy. Chemotherapy remains the mainstay of treatment for recurrent NSCLC and researchers continue to evaluate novel agents to improve the duration of survival and/or improve the quality of life for patients with this disease.

Paclitaxel is one chemotherapy agent in a class of drugs known as the taxanes. Paclitaxel (Taxol®) is frequently used in the treatment of many different types of cancer and particularly NSCLC. CT-2103 is a new formulation of paclitaxel in which a water-soluble molecule is added to the drug, thereby increasing the time it remains active in the body

In this recent phase I trial of CT-2103, 12 patients who had been previously treated with chemotherapy for NSCLC were treated with intravenous CT-2103 every 3 weeks. Following treatment with CT-2103, 1 patient (8%) had partially responded to treatment and 2 patients (17%) had stable disease. The most common side effects included decreased white blood cells (which are needed to fight infection), as well as neuropathy, a condition in which the peripheral nerves, particularly in the fingers and toes, become temporarily or permanently damaged. Neuropathy is often described as pain in the fingers and toes or as a feeling of numbness or tingling.

Scroll to Continue

Recommended Articles

Small Cell Lung Cancer

Checkpoint Inhibitor - Chemotherapy for Treatment of Small Cell Lung Cancer

Update on role of Tecentriq, Imfinzi, Opdivo, Keytruda and Adebrelimab for treatment of Small Cell Lung Cancer.

The researchers concluded that CT-2103 appears to provide anti-cancer activity in patients with recurrent NSCLC. Patients with recurrent NSCLC may wish to speak with their physician about their treatment options and the risks and benefits of participating in a clinical trial further evaluating CT-2103 or other promising therapeutic options. Two sources of information regarding ongoing clinical trials include the National Cancer Institute ( and Personalized clinical trial searches are also performed on behalf of patients at

Reference: Burris H, Shipley D, Greco A, et al. Preliminary clinical and pharmacokinetic data for CT-2103 (Xyotax™) in patients with non-small cell lung cancer (NSCLC). Lung Cancer. 2003;41;Abstract P-219.


Copyright © 2018 CancerConnect. All Rights Reserved.